EHC Q1 Deep Dive: Capacity Expansion and Staffing Drive Strong Start to 2026

Health care services provider Encompass Health (NYSE:EHC) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 9% year on year to $1.59 billion. The company expects the full year’s revenue to be around $6.42 billion, close to analysts’ estimates. Its non-GAAP profit of $1.60 per share was 7.1% above analysts’ consensus estimates.

Is now the time to buy EHC? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Encompass Health’s first quarter results for 2026 were met with a notably positive market reaction, as the company’s revenue growth outpaced Wall Street expectations. Management attributed the quarter’s performance to robust demand for inpatient rehabilitation services, improved patient discharge outcomes, and effective workforce retention strategies. CEO Mark Tarr emphasized the benefit of low nursing turnover and expanding clinical development programs in supporting operational efficiency, while also noting a 9.4% reduction in premium labor costs compared to last year. These factors, along with ongoing investments in hospital capacity, were called out as the primary forces behind the company’s solid start to the year.

Looking forward, Encompass Health’s updated outlook is shaped by ongoing capacity expansion, evolving regulatory requirements, and targeted strategies to improve Medicare Advantage admissions. Management highlighted plans to open several new hospitals and add beds to existing facilities, aiming to relieve occupancy constraints that limited volume growth. CFO Douglas Coltharp noted the impact of regulatory changes such as TEAM implementation and expanded Review Choice Demonstration, while also discussing early results from the company’s admit-and-appeal strategy for Medicare Advantage patients. As Tarr stated, “We are uniquely positioned to address this important societal need,” reflecting management’s focus on capturing underserved demand as the population ages.

Key Insights from Management’s Remarks

Management cited strong patient demand, improved staffing retention, and strategic capacity investments as the main drivers of first quarter performance.

• Staffing and turnover improvements: Encompass Health achieved its lowest registered nurse (RN) turnover rate since 2012, with annualized RN turnover at 17.8%, down from 20.2% the prior year. Management credited increased participation in clinical ladder programs, which offer professional development and higher compensation, as a key reason for both improved retention and reduced reliance on contract labor. This led to a 9.4% decline in premium labor spend year-over-year.

• Capacity constraints and expansions: The company faced occupancy challenges, with about 35% of hospitals operating above 90% occupancy, some exceeding 95%. In response, Encompass Health opened a new 49-bed hospital and added 44 beds to existing facilities during the quarter. Plans are underway to open seven additional hospitals and expand beds in high-occupancy markets, including the introduction of small-format hospitals as part of a new hub-and-spoke strategy.

• Same-store discharge trends: Same-store discharge growth was moderately impacted by recent unit closures, which reduced reported growth by about 85 basis points. Management expects discharge growth to recover as patient volumes are consolidated into other hospitals and new bed expansions come online.

• Regulatory environment: The first quarter brought significant regulatory developments, including TEAM implementation and the expansion of Review Choice Demonstration (RCD) into more states. Management emphasized preparedness for these changes and noted that while they may introduce short-term challenges, the company’s operational flexibility should help mitigate their impact.

• Medicare Advantage (MA) strategy: While nationwide MA penetration appears to have plateaued, Encompass Health has initiated an admit-and-appeal process in select markets to address initial MA admission denials. Early results show improved approval rates, and management intends to further scale this approach if trends remain favorable.

Drivers of Future Performance

Encompass Health’s guidance for the year is driven by expanding capacity, regulatory adaptation, and operational efficiency initiatives.

• Aggressive expansion plans: The company is on pace to open seven more hospitals and add 100–150 beds to existing locations this year, with a broader pipeline of projects announced for future periods. Management believes these investments are essential to meet rising demand and address occupancy-driven constraints in key markets.

• Regulatory adaptation: Management anticipates ongoing regulatory change, including recent TEAM implementation and RCD expansions, will require proactive operational adjustments. The company’s experience navigating prior regulatory shifts positions it to adapt, but leadership recognizes there may be temporary disruptions as new rules are phased in.

• Medicare Advantage opportunities and risks: The admit-and-appeal pilot for Medicare Advantage patients is expected to improve conversion rates and help offset recent volume headwinds. However, management acknowledges that success will depend on broader payer behavior, evolving reimbursement models, and the time required to scale effective solutions across the portfolio.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be tracking (1) progress on hospital openings and bed expansions to alleviate occupancy constraints, (2) the rollout and impact of the admit-and-appeal strategy for Medicare Advantage admissions, and (3) the company’s ability to adapt to new regulatory changes such as TEAM and expanded RCD. The pace of capacity additions and regulatory developments will be key markers of execution.

Encompass Health currently trades at $107.72, up from $100 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

Stocks That Trumped Tariffs

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.